Dr. Jonasch on the Promise of Belzutifan in Metastatic RCC
Eric Jonasch, MD, discusses the promise of the hypoxia inducible factor-2 alpha inhibitor belzutifan in metastatic renal cell carcinoma.
Future Directions in the Management of Renal Cell Carcinoma
Shared insight on the evolving treatment landscape of renal cell carcinoma and expectations for future evolution in the paradigm.
Novel Treatment Strategies in Non-Clear Cell Renal Cell Carcinoma
Before closing out there review of non–clear cell RCC management, expert oncologists highlight novel therapeutic strategies and ongoing clinical trials.
Dr. Jonasch on the Exploration of Cabozantinib in the Neoadjuvant Setting in RCC
Eric Jonasch, MD, discusses the exploration of cabozantinib in the neoadjuvant setting in renal cell carcinoma.
Systemic Therapy in the Treatment of Non-Clear Cell RCC: The Evolving Landscape
Moving on to discuss the management of non–clear cell renal cell carcinoma, panelists consider cornerstone treatment options in this setting.
Advanced Clear Cell RCC: Optimal Selection and Sequencing of Second-Line Therapy
Comprehensive insight to the optimal selection and sequencing of therapy for advanced clear cell RCC in the second-line setting and beyond.
Treatment Options for Advanced Clear Cell RCC in the Second-Line and Beyond
Centering their discussion on the second-line setting, expert oncologists review mainstay second-line therapies for advanced clear cell RCC.
Is There a Role for Adjuvant Therapy in Advanced Clear Cell RCC?
Expert perspectives on key clinical trials studying first-line adjuvant therapy in patients with advanced clear cell renal cell carcinoma.
First-Line Therapy in Advanced Clear Cell RCC: Novel Triplet Regimens
Focusing on novel first-line triplet therapy combinations, panelists consider which regimens may find a role in the management of advanced clear cell RCC.
First-Line Therapy in Advanced Clear Cell RCC: Novel Doublet Regimens
An expert panel reviews novel first-line doublet therapies being studied in patients with advanced clear cell renal cell carcinoma.
Advanced Clear Cell RCC: Quality of Life Data in First-Line Clinical Trials
Before closing out their review of mainstay combination therapy in the first-line setting of advanced clear cell RCC, panelists reflect on available quality of life data.
Treating Patients with Clear Cell RCC with Brain Metastases or Sarcomatoid Disease
Focused discussion on brain metastases or sarcomatoid disease in advanced clear cell RCC and the selection of first-line treatment regimens.
Advanced Clear Cell RCC: Role of Site of Metastases in Selecting First-Line Therapy
Shared insight on the importance of sites of metastases and how they may impact first-line treatment selection in advanced clear cell RCC.
Selecting the Appropriate First-Line Therapy in Advanced Clear Cell RCC
Centering conversation on systemic therapy, panelists review trial data behind the first-line combination regimens for patients with advanced clear cell RCC.
What is the Role of Nephrectomy in Advanced Clear Cell RCC?
Comprehensive insight to the role of nephrectomy over systemic therapy in patients who receive a diagnosis of advanced clear cell RCC.
Overview on Clear Cell Renal Cell Carcinoma: Prevalence and Prognosis
Expert oncologists open their discussion on advanced clear cell RCC by identifying its prevalence and prognoses before moving into treatment considerations.
Dr. Jonasch on the Target Population for Treatement with Belzutifan in RCC
Eric Jonasch, MD, discusses the best patient population when treating with belzutifan in clear cell renal cell carcinoma.
Dr. Jonasch on the Future of Belzutifan in Clear Cell RCC
Eric Jonasch, MD, discusses the future of belzutifan (Welireg) in clear cell renal cell carcinoma.
Dr. Jonasch on the Investigation of Belzutifan in ccRCC
Eric Jonasch, MD, discusses the investigation of belzutifan (Welireg) in clear cell renal cell carcinoma.
Advanced Renal Cell Carcinoma: Clinical Practice Pearls
Drs Sumeet Bhatia and Eric Jonasch highlight unmet needs in advanced renal cell carcinoma and share clinical pearls.
Role of Community and Academic Centers in the Treatment of Patients with Advanced RCC
Dr Sumeet Bhatia highlights the challenges faced by community oncologists who treat patients with advanced renal cell carcinoma and which patients they refer to academic centers.
Toxicities and Quality of Life with IO-IO Therapies in Patients with Advanced RCC
Two oncologists describe common adverse events seen with IO-IO combination treatment regimens for advanced renal cell carcinoma, and how they interpret quality of life data from the CheckMate 214 trial.
Advanced Renal Cell Carcinoma and Brain Metastases
Experts discuss how to treat advanced renal cell carcinoma with brain metastases and when to refer patients to an academic center.
Nivolumab + Ipilimumab Therapy as Frontline Therapy for Advanced Renal Cell Carcinoma
Treating a patient with advanced renal cell carcinoma with ipilimumab-nivolumab based on data from the CheckMate 214 trial.
Patient Profile Presentation: A 41-Year-Old Male with Advanced Renal Cell Carcinoma
Sumeet Bhatia, MD, presents the patient profile of a 47-year-old male patient with advanced renal cell carcinoma.
Impact of Adjuvant Pembrolizumab Approval on RCC Treatment Landscape
Two key opinion leaders review data from a phase 3 clinical trial assessing the use of lenvatinib plus pembrolizumab for the treatment of advanced renal cell carcinoma.
Adverse Events with IO-TKI Combination Treatment Regimens
Two oncologists describe common adverse events seen with I/O–TKI combination treatment regimens for advanced renal cell carcinoma and when they choose to stop the therapy.
Lenvatinib + Pembrolizumab as Frontline Therapy for Advanced Renal Cell Carcinoma
Dr Eric Jonasch discusses why he chose to treat his patient’s advanced renal cell carcinoma with lenvatinib-pembrolizumab and how he modifies the dosage throughout treatment.
Considerations for Treatment Decision Making for Advanced Renal Cell Carcinoma
Sumeet Bhatia, MD, explains the factors he considers in choosing a treatment for advanced renal cell carcinoma and the role biomarkers have in the process.
Patient Profile Presentation: A 61-Year-Old Man with Advanced Renal Cell Carcinoma
Eric Jonasch, MD, presents a real world advanced renal cell carcinoma patient profile and reviews the available first-line IO-TKI combination treatment regimens.
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
Dr In on the Increased Incidence of Gastric Cancer in Minority Patient Populations
2 Clarke Drive Cranbury, NJ 08512